Investing

Revolution Medicines : RVMD

RVMD

Stock Data

$205.15

$7.34 (3.71%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Revolution Medicines is a pioneering biotech firm focused on creating innovative treatments for cancers driven by RAS mutations. With a robust pipeline of novel targeted therapies, the company is at the forefront of precision oncology. Its leading candidates, including RMC-6236, RMC-6291, and RMC-9805, are undergoing clinical trials to tackle various RAS-addicted cancers. Additionally, Revolution Medicines is exploring combination treatments to enhance efficacy. Founded in 2014 and based in Redwood City, California, the company is dedicated to transforming cancer treatment paradigms.

Latest Activity

RVMDRevolution Medicines, Inc.

Q2 2026

Aug 5, 4:05pm ET

EPS

-$3.06

est -$2.06-48.8%

Revenue

—

est $15M—

The FDA has accepted the pancreatic cancer application for daraxonrasib, and a $151 million non-cash warrant charge drove most of the 49% miss on expectations. With $3.94 billion in cash, this pre-revenue company is funding a first commercial launch. Next catalysts: Phase 3 RASolve 307 in Q4, updated colorectal data.

Loading…

ShareRead more

All Revolution Medicines Articles

9 Articles

Gerelyn Terzo | Jul 12, 2026 at 10:44 PM EDT

5 Stock Setups Where Wall Street Sees the Most Upside Right Now

The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly…

Trey Thoelcke | Jun 24, 2026 at 7:55 AM EDT

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three…

Ian Cooper | Apr 13, 2026 at 8:31 AM EDT

Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher

The rally was nice while it lasted. Unfortunately, with the U.S. and Iran unable to agree, the war continues. Oil…

Trey Thoelcke | Apr 1, 2026 at 7:35 AM EDT

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual…

Trey Thoelcke | Feb 5, 2025 at 8:45 AM EST

Prediction: This Pharma Stock Will Be the Best Performer in 2025

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Trey Thoelcke | Dec 15, 2024 at 8:20 AM EST

Insiders Are Loving These 6 Stocks Right Now

The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as…

Lee Jackson | Mar 1, 2023 at 8:48 AM EST

Wednesday’s Top Analyst Upgrades and Downgrades: Broadcom, Clean Energy Fuels, Dish Network, Occidental Petroleum, Workday and More

Wednesday's top analyst upgrades and downgrades included Broadcom, Clean Energy Fuels, Dish Network, First Republic Bank, Gaming and Leisure Properties,…

Chris Lange | Oct 21, 2022 at 8:54 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: AT&T, Exxon Mobil, Hasbro, Moderna, Snap, Under Armour and More

Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical,…

Jon C. Ogg | Mar 9, 2020 at 9:19 AM EDT

Top Analyst Upgrades and Downgrades: Oil E&Ps, Amex, ADT, Gilead, Logitech, PACCAR, Regions, Stamps.com, Vivint Smart Home and More

Monday's top analyst upgrades, downgrades and initiations included American Express, ADT, Gilead Sciences, Logitech, PACCAR, Regions Financial, Stamps.com and Vivint…